July 18th 2018EP. 1: Significance of KEYNOTE-189 in NSCLC
July 18th 2018EP. 2: Bevacizumab in NSCLC
July 18th 2018EP. 3: Ramucirumab in Relapsed/Refractory NSCLC
July 18th 2018EP. 4: The Phase 3 REVEL Trial in NSCLC
July 18th 2018EP. 5: VEGF Inhibition in NSCLC
July 18th 2018EP. 6: Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC
July 18th 2018EP. 7: Future Use of Antiangiogenic Agents in NSCLC
July 18th 2018EP. 8: Evidence for Immunotherapy in Frontline NSCLC
July 18th 2018EP. 9: Considerations for Antiangiogenic Therapy in NSCLC
July 18th 2018EP. 10: Key Points From the REVEL Trial in NSCLC
July 18th 2018EP. 11: Breakthroughs in Treating NSCLC
July 18th 2018EP. 12: Antiangiogenic Therapy in NSCLC
July 18th 2018EP. 13: Pembrolizumab in First-Line Nonsquamous NSCLC
July 18th 2018EP. 14: Rationale for Ramucirumab in NSCLC
July 18th 2018EP. 15: Necitumumab in Squamous NSCLC
July 18th 2018EP. 16: Antiangiogenic Therapy in NSCLC: Addressing the Unknown
July 18th 2018EP. 17: Using Antiangiogenic Therapy in NSCLC in the Future
July 18th 2018EP. 18: Sequencing Therapy in NSCLC
